Steven H Itzkowitz, MD Email Steven Itzkowitz
- PROFESSOR | Medicine, Gastroenterology
- PROFESSOR | Oncological Sciences
- Hospital Affiliations
- The Mount Sinai Hospital
- Mount Sinai St. Luke's and Mount Sinai West
- Feinstein IBD Clinical Center 212-241-8100212-241-8100
Dr. Itzkowitz has served as a Study Section member for the National Cancer Institute, Veteran's Affairs Merit Review Board, Crohn's and Colitis Foundation of America, and US-Israel Binational Science Foundation, and as an editor of the International Journal of Colorectal Disease, and Gut and Liver, and associate editor of Inflammatory Bowel Diseases, Clinical Gastroenterology and Hepatology, and Gastric Cancer. He spearheaded efforts to secure NCI funding for the East Harlem Partnership for Cancer Awareness: a program based at Mount Sinai, designed to raise awareness in the East Harlem community regarding the risks and treatment for several common cancers including colon cancer.
Dr. Itzkowitz's research interests are in the field of gastrointestinal cancer. His laboratory conducts research into the microbiome of patients with inflammatory bowel disease (IBD). Clinical studies have focused on detecting and preventing colon cancer in inflammatory bowel disease, reducing disparities in colon cancer screening, and developing new non-invasive stool DNA tests for colon cancer.
In the News: Dr. Steven Itzkowitz was recently featured in INSIDE MOUNT SINAI for his work in increasing screening colonoscopy rates in NYC with the C5 Coalition.
- Colon Polypectomy
- Colon Polyps
- Colorectal Cancer
- Crohn's Disease
- Familial Adenomatous Polyposis
- Flexible Sigmoidoscopy
- Inflammatory Bowel Disease
- Iron-Deficiency Anemia
- Lynch Syndrome
- Peutz Jeghers Syndrome
- Polyposis Syndromes
- Rectal Cancer
- Ulcerative Colitis
- Upper GI Endoscopy
Aerodigestive Tract, Cancer, Epithelial Cells, Inflammatory Bowel Disease (IBD)
Multi-Disciplinary Training Area
Cancer Biology [CAB]
MD, Mount Sinai School of Medicine
Residency, Internal Medicine
Bellevue/NYU Hospital Center
Residency, Internal Medicine
Bellevue/NYU Hospital Center
University of Cal. San Francisco
Excellence in Teaching Award
Institute for Medical Education; Mount Sinai School of Medicine
Patient Advocacy Award
East Harlem Health Outreach Project (EHHOP)
Arnold P. Gold Foundation for Humanism
Academic Achievement Award (Senior Faculty)
Faculty Council, Mount Sinai School of Medicine
Alpha Omega Alpha Medical Honor Society, Mount Sinai School of Medicine
Castle Connolly and New York Magazine
Cancer Risk in Patients with Inflammatory Bowel Disease
Many patients with inflammatory bowel disease (IBD) take medicines that affect their immune system. Most of these drugs were initially tested in patients with IBD who did not have a past history of cancer for fear that these agents might promote a recurrence or development of a new cancer. But a recent study by Dr. Itzkowitz and coworkers indicates that even in those patients with IBD who have a history of cancer, taking immune modulating medicines did not predispose them to a recurrence of their cancer or the development of a new cancer. Dr. Itzkowitz is now heading a multicenter registry to follow patients with IBD who have a history of cancer to track their rates of new or recurrent cancer in a prospective fashion.
Mechanisms of inflammation-associated carcinogenesis
Laboratory investigation is exploring the profile of intestinal microbiota in patients with inflammatory bowel disease (IBD) who have primary sclerosing cholangitis - conditions that predispose to colon cancer.
Reducing disparities in screening colonoscopy
Dr. Itzkowitz helped spearhead community outreach efforts to enhance awareness of colon cancer in East Harlem. He and his colleagues have demonstrated the effectiveness of new strategies to improve the completion rates of screening colonoscopy among minority individuals by employing patient navigators within an open access referral system. This model has now been accepted by most medical centers and ambulatory clinics.
Progression of Neoplasia in Inflammatory Bowel Disease
Studies at Mount Sinai are examining clinical and pathological risk factors to help better understand the factors that promote progression from inflammation to precancerous and cancerous lesions in the colon in patients with IBD. Dr. Itzkowitz is the PI on a new registry that will follow patients with IBD and a past history of cancer who are treated with immune modulating medicines for their IBD, in order to determine whether these medications are associated with the development of recurrent or new cancers.
Developing non-invasive colon cancer screening tests
Dr. Itzkowitz's team was part of a national study that demonstrated the utility of stool DNA testing for detecting colon cancer and precancerous polyps in the general population. He is now leading a national study that is testing a modified version of the stool DNA test in patients with IBD who are at increased risk for developing colorectal cancer.
Torres J, Bao X, Goel A, Colombel JF, Pekow J, Jabri B, Williams KM, Castillo A, Odin JA, Meckel K, Fasihuddin F, Peter I, Itzkowitz S, Hu J. The features of mucosa-associated microbiota in primary sclerosing cholangitis. Alimentary pharmacology & therapeutics 2016 Apr; 43(7).
Itzkowitz SH, Winawer SJ, Krauskopf M, Carlesimo M, Schnoll-Sussman FH, Huang K, Weber TK, Jandorf L. New York Citywide Colon Cancer Control Coalition: A public health effort to increase colon cancer screening and address health disparities. Cancer 2016 Jan; 122(2).
Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V, Hoffman G, Agrawal M, Lukin D, Desai A, McEachern E, Bosworth B, Scherl E, Reyes A, Zaidi H, Mudireddy P, DiCaprio D, Sultan K, Korelitz B, Wang E, Williams R, Chen L, Katz S, Itzkowitz S. Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2016 Jan; 14(1).
Ladabaum U, Mannalithara A, Jandorf L, Itzkowitz SH. Cost-effectiveness of patient navigation to increase adherence with screening colonoscopy among minority individuals. Cancer 2015 Apr; 121(7).
Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. The New England journal of medicine 2015 Apr; 372(15).
Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM. Multitarget stool DNA testing for colorectal-cancer screening. The New England journal of medicine 2014 Apr; 370(14).
Lee KK, Jandorf L, Thélèmaque L, Itzkowitz SH. Colorectal neoplasia detection among black and Latino individuals undergoing screening colonoscopy: a prospective cohort study. Gastrointestinal endoscopy 2014 Mar; 79(3).
Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, Rozenfeld N, Harpaz N, Itzkowitz S, Harris CC, Rotter V, Gorgoulis VG, Oren M. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer cell 2013 May; 23(5).
Bernheim O, Colombel JF, Ullman TA, Laharie D, Beaugerie L, Itzkowitz SH. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut 2013 Nov; 62(11).
Jandorf L, Stossel LM, Cooperman JL, Graff Zivin J, Ladabaum U, Hall D, Thélémaque LD, Redd W, Itzkowitz SH. Cost analysis of a patient navigation system to increase screening colonoscopy adherence among urban minorities. Cancer 2013 Feb; 119(3).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Itzkowitz during 2017 and/or 2018. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Bio-Rad Laboratories, Inc.
Scientific Advisory Board:
- EXACT Sciences Corporation
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.